# **Special Issue**

# Polysaccharide-Based Nanoparticles for Theranostic Nanomedicine

### Message from the Guest Editor

Due to the enhanced permeability and retention (EPR) effect, nanocarriers can be highly enriched in tumor sites, which is conducive to enhance the circulation time of drugs and enhance the stability of drugs, so they have become a powerful means to enhance the effect of tumor treatment and diagnosis. As a natural biomacromolecule, polysaccharide has good biocompatibility and biological function, and can realize active targeting. For example, hyaluronic acid has the function of specifically targeting CD44 receptor. Natural polysaccharides have become a good carrier for nano delivery systems because of their biocompatibility, biodegradability, low toxicity and unique physical and chemical properties such as hydrophilicity, positive charge and easy modification. Polysaccharide nanoparticles not only have the dual advantages of nanotechnology and polysaccharide, but also have the specificity of highly targeted drug delivery and molecular imaging in the application of theranostic nanomedicine. Polysaccharide based nanoparticles are increasingly used as platforms for simultaneous drug delivery and imaging, so they have become popular therapeutic nanoparticles.

### **Guest Editor**

Prof. Dr. Jingdi Chen Marine College, Shandong University, Weihai 264209, China

### Deadline for manuscript submissions

closed (10 September 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## mdpi.com/si/96612

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

